2.38
前日終値:
$2.43
開ける:
$2.38
24時間の取引高:
7,970
Relative Volume:
0.31
時価総額:
$16.71M
収益:
-
当期純損益:
$-7.72M
株価収益率:
-0.9017
EPS:
-2.6394
ネットキャッシュフロー:
$-6.25M
1週間 パフォーマンス:
+5.31%
1か月 パフォーマンス:
+19.00%
6か月 パフォーマンス:
+32.96%
1年 パフォーマンス:
-49.28%
Edesa Biotech Inc Stock (EDSA) Company Profile
EDSA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
EDSA
Edesa Biotech Inc
|
2.38 | 17.07M | 0 | -7.72M | -6.25M | -2.6394 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Edesa Biotech Inc (EDSA) 最新ニュース
What analysts say about Edesa Biotech Inc. stockFree Investment Timing Strategies - jammulinksnews.com
Edesa Biotech Inc. Stock Analysis and ForecastConsistent double returns - jammulinksnews.com
Is Edesa Biotech Inc. a good long term investmentOverwhelming profit margins - Autocar Professional
What drives Edesa Biotech Inc. stock priceFree Consultation - printweek.in
Edesa Biotech Insiders May Regret Not Buying More, Market Cap Hits US$16m - simplywall.st
What makes Edesa Biotech Inc. stock price move sharplyElite Stock Shortlist - Newser
How Edesa Biotech Inc. stock performs during market volatilityGrowth Stock Monitor - Newser
Why Edesa Biotech Inc. stock attracts strong analyst attentionMomentum Swing Watchlist - Newser
Edesa Biotech's JUST BREATHE Study Advances ARDS Treatment with Promising Progress - AInvest
Edesa Biotech Advances ARDS Treatment with JUST BREATHE Study - TipRanks
Edesa Biotech (NASDAQ:EDSA) Shares Down 1% – Here’s Why - Defense World
H.C. Wainwright Maintains Edesa Biotech(EDSA.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
Edesa Biotech secures up to C$23 million in funding under the Federal Government’s Strategic Innovation Fund for pivotal clinical study - Fasken
Edesa Biotech, Inc. closes US$10 million bought deal offering of common shares - Fasken
Edesa Biotech completes US$15 million private placement - Fasken
40,944 Shares in Edesa Biotech, Inc. (NASDAQ:EDSA) Bought by Citadel Advisors LLC - Defense World
Edesa Biotech Shareholders Approve Key Proposals at AGM - TipRanks
Edesa Biotech (EDSA) Receives Buy Rating from Lucid Capital | ED - GuruFocus
Zacks Small Cap Reduces Earnings Estimates for Edesa Biotech - Defense World
EDSA: Advancing EB06 for the Treatment of Vitiligo - Research Tree
EDSA: Advancing EB06 for the Treatment of Vitiligo… - Yahoo Finance
Positive Signs As Multiple Insiders Buy Edesa Biotech Stock - Yahoo Finance
Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results - GlobeNewswire
Edesa Biotech Shifts Focus to Vitiligo Treatment in Q2 2025 - TipRanks
Edesa Biotech Q2 EPS USD -0.3 - marketscreener.com
Edesa Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Edesa Biotech Reports Q2 2025 Financial Results and Advances Vitiligo Drug Development Efforts - Nasdaq
Edesa Biotech Advances Novel Vitiligo Treatment with $15M Backing from Healthcare Investors - Stock Titan
Edesa Biotech Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
Edesa Biotech (EDSA) to Release Quarterly Earnings on Friday - Defense World
Edesa Biotech to Present at 2024 Bloom Burton Healthcare Investor Conference - TipRanks
Edesa Biotech to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference in Toronto - Nasdaq
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference - GlobeNewswire
Edesa Biotech Showcases Immuno-Inflammatory Pipeline at Bloom Burton Healthcare Conference - Stock Titan
Edesa Biotech Inc (EDSA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):